Skip to main content
SpringerLink
Log in

Vergleich der Gewebegängigkeit von Erythromycin

Tissue penertration of erythromycin. A Comparative review

  • Published:
Infection Aims and scope Submit manuscript

Zusammenfassung

Obgleich Erythromycin seit mehr als 25 Jahren in der Therapie benutzt wird, fehlt bisher eine zusammenfassende Darstellung seiner Gewebegängigkeit. In der vorliegenden Übersicht werden neben den bei verschiedenen Derivaten in Dosis- und Zeitabhängigkeit nach oraler Gabe erreichbaren Serumspiegelspitzen die Erythromycin-Gewebespiegel ausführlich dokumentiert. Die Höhe der Spiegel im Gewebe übertrifft häufig die entsprechenden MHK-Werte Erythromycin-empfindlicher Erreger um ein Mehrfaches. Das Zentralnervensystem wird jedoch von Erythromycin nicht, bzw. nur in sehr geringem und nicht vorhersehbarem Ausmaß erreicht. Ähnliches gilt für die Plazenta-Passage des Erythromycins. Die Gewebespiegel bestätigen in Hinblick auf die MHK-Werte des Erregerspektrums die klinischen Erfahrungen für eine Therapie mit Erythromycin bei Infektionen des HNO-Bereiches und der Atemwege, sowie — mit gewissen Einschränkungen — bei Chlamydien-Urethritis.

Summary

Tissue Penetration of Erythromycin. A Comparative Review. Although erythromycin has been used in therapy for more than 25 years, until now there has been no paper summarizing the data on tissue penetration. The present review documents in detail dose- and time-related peak serum levels of erythromycin derivatives after oral administration, in addition to the erythromycin tissue levels. The erythromycin tissue levels often manifoldly exceed the corresponding MIC values of pathogens sensitive to erythromycin. However, erythromycin does not penetrate the central nervous system, or only penetrates in small, incalculable amounts. The same applies for the placental passage of erythromycin. The tissue levels confirm, with respect to the MIC values of the pathogen spectrum, clinical experience with erythromycin in the treatment of ear, nose and throat infections, respiratory tract infections and, with some limitationsChlamydia urethritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Lacey, R. W. A new look at erythromycin. Postgrad. Med. J. 53 (1977) 195–200.

    Google Scholar 

  2. Knothe, H. A review of the medical considerations of the use of tylosin and other macrolide antibiotics as additives in animal feeds. Infection 5 (1977) 183–187.

    Google Scholar 

  3. Sherlock, S. Hepatic reactions to therapeutic agents. Ann. Rev. Pharmacol. 5 (1965) 429–446.

    Google Scholar 

  4. Dette, G. A.: Taux de concentration sérique et tissulaire de l'Erythromycine. Gaz. Méd. (1979) im Druck.

  5. Griffith, R. S., Stephens, V. C., Wolfe, R. N., Boniece, W. S., Lee, C. C. Preliminary studies on propionyl erythromycin. Antibiot. Med. Clin. Ther. 5 (1958) 609–613.

    Google Scholar 

  6. Josselyn, L. E., Endicott, C., Sylvester, J. C. Absorption of erythromycin. III. Various pharmaceutical forms. Antibiot. Ann. 1954–1955 (1955) 279–282.

    Google Scholar 

  7. Gavrilina, T. N., Lagert, I. K. Эритромицин в лечении хроническин пневмонип. Ter. Arkh. 36 (1964) 40–44.

    Google Scholar 

  8. Perry, D. M., Hall, G. A., Kirby, W. M. M. Triacetyloleandomycin and erythromycin: a comparison of in vitro activity and of blood levels obtained after oral administration. Antibiot. Med. Clin. Ther. 6 (1959) 347–352.

    Google Scholar 

  9. Griffith, R. S., Black, H. R. A comparison of blood levels after oral administration of erythromycin and erythromycin estolate. Antibiot. Chemother. 12 (1962) 398–403.

    Google Scholar 

  10. Griffith, R. S. Laboratory and clinical studies with erythromycin propionate. Antibiot. Ann. 1958–1959 (1959) 364–374.

    Google Scholar 

  11. Josselyn, L. E., Sylvester, J. C. Absorption of erythromycin. Antibiot. Chemother. 3 (1953) 63–66.

    Google Scholar 

  12. Grigsby, M. E., Johnson, J. B., Simmons, G. W. Some laboratory and clinical experiences with erythromycin. Antibiot. Chemother. 3 (1953) 1029–1034.

    Google Scholar 

  13. Kirby, W. M. M., Maple, F. M., O'Leary, B. Erythromycin serum concentrations following administration in acid-resistant tablets. Antibiot. Chemother. 3 (1953) 473–477.

    Google Scholar 

  14. Männistö, P., Tuomisto, J., Räsänen, R. Absorption of erythromycin. A cross-over study in healthy volunteers. Arzneim. Forsch. 25 (1975) 1828–1831.

    Google Scholar 

  15. Smith, J. W., Dyke, R. W., Griffith, R. S. Absorption following oral administration of erythromycin. J. Am. Med. Ass. 151 (1953) 808–810.

    Google Scholar 

  16. Heilman, F. R., Herrell, W. E., Wellman, W. E., Geraci, J. E. Some laboratory and clinical observations on a new antibiotic, erythromycin (Ilotycin). Proc. Staff Meet. Mayo Clin. 27 (1952) 285–304.

    Google Scholar 

  17. Parsons, R. L., Paddock, M., Hossack, A. Particular aspects of the pharmacokinetics of erythromycin. Infection 5 Suppl. 1 (1977) 23–28.

    Google Scholar 

  18. Coyne, T. C., Shum, S., Chun, A. H. C., Jeansonne, L., Shirkey, H. C.: Bioavilability of erythromycin ethylsuccinate in pediatric patients. J. Clin. Pharmacol. (1978) 194–202.

  19. Vanhoof, R., Clumeck, N., Demol, P., Vanderlinden, M. P., Butzler, J. P., Yourassowsky, E. Clinical and pharmacological evaluation of erythromycin ethylsuccinate in patients with chronic bronchitis. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 34–37.

    Google Scholar 

  20. Simon, C., Clasen, I. Sputum levels of erythromycin after single and repeated oral administration in adult patients with bronchitis. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 19–22.

    Google Scholar 

  21. Hirsch, H. A., Finland, M. Effect of food on the absorption of erythromycin propionate, erythromycin stearate, and triacetyloleandomycin. Am. J. Med. Sci. 237 (1959) 693–709.

    Google Scholar 

  22. Hall, G. A., Roberts, C. E., Perry, D. M., Kirby, W. M. M. Erythromycin stearate and propionyl erythromycin: a comparison of blood levels obtained after oral administration. Antibiot. Med. Clin. Ther. 7 (1960) 231–234.

    Google Scholar 

  23. Hirsch, H. A., Kunin, C. M., Finland, M. Antibacterial activity of serum of normal men after oral doses of erythromycin propionate and triacetyloleandomycin. N. Engl. J. Med. 260 (1959) 408–412.

    Google Scholar 

  24. Perry, D. M., Hall, G. A., Kirby, W. M. M. Clinical and laboratory studies of erythromycin propionate. Antibiot. Ann. 1958–1959 (1959) 375–381.

    Google Scholar 

  25. Griffith, R. S., Black, H. R. Comparison of the blood levels obtained after single and multiple doses of erythromycin estolate and erythromycin stearate. Am. J. Med. Sci. 247 (1964) 69–74.

    Google Scholar 

  26. Bell, S. M.: A comparison of absorption after oral administration of erythromycin estolate and erythromycin stearate. Med. J. Austr. (1971) 1280–1283.

  27. Malmborg, A. S. Absorption of erythromycin stearate after oral administration. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 15–18.

    Google Scholar 

  28. Sylvester, J. C., Josselyn, L. E. Absorption of erythromycin. II. Erythromycin stearate. Antibiot. Chemother. 3 (1953) 930–932.

    Google Scholar 

  29. Triggs, E. J., Ashley, J. J.: Oral administration of erythromycin stearate: effect of dosage form on plasma levels. Med. J. Austr. (1978) 121–123.

  30. Wiegand, R. G., Chun, A. H. C. Serum protein binding of erythromycin and erythromycin 2′-propionate ester. J. Pharm. Sci. 61 (1972) 425–428.

    Google Scholar 

  31. Lopez-Belio, M., Takimura, Y., Fornatto, E. J., Holinger, P H. Erythromycin in the bronchial tree after oral, intravenous, and aerosol administration. Antibiot. Ann. 1956–1957 (1957) 152–158.

    Google Scholar 

  32. Fraschini, F., Copponi, V., Dubini, F., Scarpazza, G. Concentration of erythromycin and ampicillin in bronchial secretions of patients with chronic respiratory infections. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 23–27.

    Google Scholar 

  33. Eliasson, R., Malmborg, A. S., Dornbusch, K., Kvist, U. Secretion of erythromycin into human semen: methodological, experimental and clinical aspects. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 31–33.

    Google Scholar 

  34. Lopez-Belio, M., Takimura, Y. Intrapleural, intravenous, and oral administration of erythromycin. Antibiot. Ann. 1954–1955 (1955) 295–311.

    Google Scholar 

  35. Spitzy, K. H., Hitzenberger, G. The distribution volume of some antibiotics. Antibiot. Ann. 1957–1958 (1958) 996–1003.

    Google Scholar 

  36. Welling, P. G., Craig, W. A. Pharmacokinetics of intravenous erythromycin. J. Pharmaceut. Sci. 67 (1978) 1057–1059.

    Google Scholar 

  37. Lee, C. C., Anderson, R. C., Chen, K. K. Tissue distribution of erythromycin in rats. Antibiot. Chemother. 3 (1953) 920–924.

    Google Scholar 

  38. Akashi, T., Kaneko, T., Sasa, T., Matsui, H. Chemical determination and clinical application of antibiotics of the erythromycin and leucomycin group. Abstr. Jap. Med. 1 (1960) 36.

    Google Scholar 

  39. Benazet, F., Dubost, M. Apparent paradox of antimicrobial activity of spiramycin. Antibiot. Ann. 1958–1959 (1959) 211–220.

    Google Scholar 

  40. Anderson, R. C., Lee, C. C., Worth, H. M., Harris, P. N. Pharmacology and toxicology of propionyl erythromycin ester lauryl sulfate. J. Am. Pharm. Ass. 48 (1959) 623–628.

    Google Scholar 

  41. Koroleva, V. G., Vasilev, V. K. сравнительная оценка всасывания и распределения различных препаратов Эритромицина при парентеральном применении. Antibiotiki 13 (1968) 431–434.

    Google Scholar 

  42. Lee, C. C., Anderson, R. C., Bird, H. L., Chen, K. K. Reabsorption of erythromycin and a microbiologically active metabolite in the bile of dogs and rats. Antibiot. Ann. 1953–1954 (1954) 493–495.

    Google Scholar 

  43. Brusch, J. L., Barza, M., Brown, R. B., Bergeron, M. G., Weinstein, L. Comparative pharmacokinetics of thirteen antibiotics in dogs. With especial reference to concentrations in liver, kidney, bile and urine. Infection 4 Suppl. 2 (1976) 82–90.

    Google Scholar 

  44. Uberti, E. Ricerche sulla eliminazione della eritromicina nelle vie biliari patologiche dell'uomo. Giornale Ital. Chemother. 3 (1956) 36–41.

    Google Scholar 

  45. Lee, C. C., Anderson, R. C., Chen, K. K. Site of absorption of erythromycin in rats. Antibiot. Chemother. 4 (1954) 926–930.

    Google Scholar 

  46. Chabbert, Y., Boyer, F., Saviard, M., Boulingre, H., Hervé, J. Determination de l'action bactéricide in vivo des antibiotiques dans la staphylococcie rénale de la souris. Ann. Inst. Pasteur 92 (1957) 760–777.

    Google Scholar 

  47. Griffith, R. S., Johnstone, D. M., Smith, J. W. The distribution and excretion of erythromycin following intravenous injection. Antibiot. Ann. 1953–1954 (1954) 496–499.

    Google Scholar 

  48. Winningham, D. G., Nemoy, N. J., Stamey, T. A. Diffusion of antibiotics from plasma into prostatic fluid. Nature (London) 219 (1968) 139–143.

    Google Scholar 

  49. Madsen, P. O., Baumueller, A., Hoyme, U. Experimental models for determination of antimicrobials in prostatic tissue, interstitial fluid and secretion. Scand. J. Infect. Dis. Suppl. 14 (1978) 145–150.

    Google Scholar 

  50. Documenta Geigy. Wissenschaftliche Tabellen. J. R. Geigy, Basel, 1968, p. 678.

  51. Armstrong, J. R., Cook, F. E., Robison, J. R. Concentration of antibiotic and chemotherapeutic agents in the ejaculum. J. Urol. 100 (1968) 72–76.

    Google Scholar 

  52. Dette, G. A., Knothe, H., Schäfer, V., Maassen, W., Wadoud, E. The effect of bromhexine on erythromycin concentrations in serum and lung tissue. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 38–41.

    Google Scholar 

  53. Zinnemann, K. Haemophilus influenzae and its pathogenicity. Curr. Top. Microbiol. Immunol. 33 (1960) 307–368.

    Google Scholar 

  54. Neaverson, M. A. Intravenous administration of erythromycin: serum, sputum and urine levels. Curr. Med. Res. Opinion 4 (1976) 359–364.

    Google Scholar 

  55. Gould, J. C. The action of erythromycin and penicillin on the bacterial flora in tonsil tissue. Chemotherapy 1 (1976) 319–325.

    Google Scholar 

  56. Georgiew, S., Gröger, H., Flood, M. K. Comparative serum and tissular tissue concentration of two macrolides. J. Antimicrob. Chemother. 4 (1978) 472–473.

    Google Scholar 

  57. Sundberg, L., Eden, T., Ernstson, S. Penetration of erythromycin into middle ear secretions: a preliminary report. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 28–30.

    Google Scholar 

  58. Bass, J. W., Steele, R. W., Wiebe, R. A., Dierdorff, E. P. Erythromycin concentrations in middle ear exudates. Pediatrics 48 (1971) 417–422.

    Google Scholar 

  59. Kaminszczick, J., Galan, H.: Interés del estudio de los niveles tisulares de antibióticos en sinusopatías. Sem. Med. (Buenos Aires) (1971) 1280–1285.

  60. Kalm, O., Kamme, C., Bergström, B., Löfkvist, T., Norman, O. Erythromycin stearate in acute maxillary sinusitis. Scand. J. Infect. Dis. 7 (1975) 209–217.

    Google Scholar 

  61. Lamberg, H. P. Clincal significance of tissue penetration of antibiotics in the respiratory tract. Scand. J. Infect. Dis. Suppl. 14 (1978) 262–266.

    Google Scholar 

  62. Gross, A., Uotinen, K. G. Elimination of antibiotics in submaxillary and parotid saliva of unanesthetized dogs. Pharmacol. Therapeut. Dentistry 1 (1970) 46–55.

    Google Scholar 

  63. LoRusso, D., Tomasetti, L. Ricerche sull'eliminazione di eritromicina da parte delle diverse ghiandole salivari. Boll Mal. Orecch. 83 (1965) 606–617.

    Google Scholar 

  64. Grady, J. E., Stern, K. F.: Penetration of lincomycin into bone. Antimicrob. Agents Chemother. (1965) 201–205.

  65. Anderson, R. C., Harris, P. N., Chen, K. K. The toxicity and distribution of “Ilotycin”. J. Am. Pharm. Ass. 41 (1952) 555–559.

    Google Scholar 

  66. Mosijchuk, N. M. проницаемость гематоэнцефалическ ого Барьера для антиБиот иков у Больных гнойным менингитом. Zh. Nevropat. Psikhat. 68 (1961) 338–342.

    Google Scholar 

  67. Lee, C. C., Froman, R. Passage of erythromycin into the aqueous humor. Antibiot. Chemother. 11 (1961) 107–109.

    Google Scholar 

  68. Furgiuele, F. P. New antibiotics: their intraocular penetration. Part II. Amer. J. Ophthal. 58 (1964) 443–447.

    Google Scholar 

  69. Moya, F.: Mechanisms of drug transfer across the placenta with particular reference to chemotherapeutic agents. Antimicrob. Agents Chemother. (1965) 1051–1057.

  70. Kiefer, L., Rubin, A., McCoy, J. B., Foltz, E. L. The placental transfer of erythromycin. Amer. J. Obstet. Gynecol. 69 (1955) 174–177.

    Google Scholar 

  71. v. Kobyletzki, D., Strauch, D. Experimentelle Untersuchungen zur Frage der diaplazentaren Passage und der Ausscheidung mit der Muttermilch von Erythromycin-Estolat (PELS). Z. Geburtsh. Gynäk. 162 (1964) 36–45.

    Google Scholar 

  72. v. Kobyletzki, D. Über die Beinflussung des Neugeborenen durch die Verabfolgung von Medikamenten unter der Geburt. Geburtsh. Frauenheilk. 25 (1965) 351–356.

    Google Scholar 

  73. Philipson, A., Sabath, L. D., Charles, D. Transplacental passage of erythromycin and clindamycin. N. Engl. J. Med. 288 (1973) 1219–1221.

    Google Scholar 

  74. South, M. A., Short, D. H., Knox, J. M. Failure of erythromycin estolate therapy in utero syphilis. J. Am. Med. Ass. 190 (1964) 182–183.

    Google Scholar 

  75. Rasmussen, F. Mammary excretion of benzylpenicillin, erythromycin, and penethamate hydroiodide. Acta Pharmacol. Toxicol. 16 (1959) 194–200.

    Google Scholar 

  76. Knowles, J. A. Excretion of drugs in milk — a review. J. Pediatr. 66 (1965) 1068–1082.

    Google Scholar 

  77. v. Kobyletzki, D. Eigene Untersuchungen über die Pharmakokinetik während der Peripartalzeit und Stillzeit. Med. Welt 19 (1968) 2010–2019.

    Google Scholar 

  78. Documenta Geigy. Wissenschaftliche Tabletten. J. R. Geigy, Basel, 1968, p. 684.

  79. Kislak, J. W., Razavi, L. M. B., Daly, A. K., Finland, M. Susceptibility of pneumococci to nine antibiotics. Am. J. Med. Sci. 250 (1965) 261–268.

    Google Scholar 

  80. Finland, M., Garner, C., Wilcox, C., Sabath, L. D.: Susceptibility of pneumococci and Haemophilus influenzae to antibacterial agents. Antimicrob. Agents Chemother. (1976) 274–287.

  81. Cleary, T. J., Villa, S., Sands, L., Hoffman, T. A. Comparative in vitro activity of josamycin, erythromycin, clindamycin and penicillin. Curr. Ther. Res. 23 (1978) 351–357.

    Google Scholar 

  82. Marks, M. I. In vitro activity of clindamycin and other antimicrobials against gram-positive bacteria and Haemophilus influenzae. CMA J. 112 (1975) 170–173.

    Google Scholar 

  83. Garrod, L. P., Lambert, H. P., O'Grady, F.: Antibiotic and Chemotherapy. E. & S. Livingstone, Edigburgh, 1973, p. 168.

  84. Griffith, R. S., Black, H. R. Erythromycin. Med. Clin. N. Amer. 54 (1970) 1199–1215.

    Google Scholar 

  85. Dixon, J. M. S., Lipinski, A. E., Graham, M. E. P. Detection and prevalence of pneumococci with increased resistance to penicillin. CMA J. 117 (1977) 1159–1161.

    Google Scholar 

  86. Romansky, M. J., Nasou, J. P., Davis, D. S., Ritts, R. E. Clinical spectrum of erythromycin as evaluated in 260 patients. J. Am. Ass. 164 (1957) 1197–1204.

    Google Scholar 

  87. Jones, W., Feldman, H., Finland, M. Susceptibility of hemolytic streptococci, other than those of group D, to eleven antibiotics in vitro. Am. J. Clin. Path. 27 (1957) 159–169.

    Google Scholar 

  88. Yoshioka, H., Rudoy, R., Riley, H. D., Yoshida, K. Antibiotic susceptibilities of 120 strains ofStaphylocossus aureus isolated from patients at a children's hospital. Decline of hospital staphylococci as compared with staphylococci in outpatients. A reversal. Clin. Pediatrics 15 (1976) 428–431.

    Google Scholar 

  89. Kim, H. B., Okumoto, M., Smolin, G. Quantitative antibiotic sensitivity determinations ofStaphylococcus aureus isolated from eye cultures. Arch. Ophthalmol. 95 (1977) 1065–1067.

    Google Scholar 

  90. Hassam, Z., Shaw, E. J., Shooter, R. A., Caro, D. B.: Changes in antibiotic sensitivity in strains ofStaphylococcus aureus, 1952–78. Br. Med. J. (1978) 536–537.

  91. Wallmark, G., Finland, M. Phage types and antibiotic susceptibility of pathogenic staphylococci. J. Am. Med. Ass. 175 (1961) 886–897.

    Google Scholar 

  92. Waisbren, B. A., Strelitzer, C. L. A five year study of the antibiotic sensitivities and cross resistances of staphylococci in a general hospital. Antibiot. Ann. 1957–1958 (1958) 350–364.

    Google Scholar 

  93. Haight, T. H., Finland, M. The antibacterial action of erythromycin. Proc. Soc. Exp. Biol. Med. 81 (1952) 175–183.

    Google Scholar 

  94. Castete, M., Mora, M.: Sensibilité aux antibiotiques deCorynebacterium diphtheriae. Presse Méd. (1974) 962.

  95. Simon, C., Bontemps, M., Wiese, K., Schewior-Roland, R. Zur Ampicillin-Therapie des Keuchhustens. Dtsch. Med. Wschr. 94 (1969) 2435–2437.

    Google Scholar 

  96. Bass, J. W., Crast, F. W., Kotheimer, J. B., Mitchell, J. A. Susceptibility ofBordetella pertussis to nine antimicrobial agents. Amer. J. Dis. Child 117 (1969) 276–280.

    Google Scholar 

  97. Jao, R. L., Finland, M. Susceptibility ofMycoplasma pneumoniae to 21 antibiotics in vitro. Amer. J. Med. Sci. 253 (1967) 639–650.

    Google Scholar 

  98. Williams, J. D., Andrews, J.: Sensitivity ofHaemophilus influenzae to antibiotics. Brit. Med. J. (1974) 134–137.

  99. Khan, W., Ross, S., Zaremba, E. A.: Comparative inhibition ofHaemophilus influenzae by eight antibiotics. Antimicrob. Agents Chemother. (1966) 393–396.

  100. Gordon, R. C., Thompson, T. R., Stevens, L. I., Carlson, W. H.: In vitro susceptibility ofHaemophilus influenzae to eight antibiotics. Antimicrob. Agents Chemother. (1974) 114–115.

  101. McBride, V. E., Dowling, H. F., Mellody, M.: Comparison of tube and plate methods for testing combinations of antibiotics againstHaemophilus influenzae. Antimicrob. Agents Chemother. (1965) 267–272.

  102. Gould, J. C. Erythromycin in respiratory tract infection. Scot. Med. J. 22 (1977) 355–359.

    Google Scholar 

  103. McLinn, S. E., Nelson, J. D., Haltalin, K. C. Antimicrobial susceptibility ofHaemophilus influenzae. Pediatrics 45 (1970) 827–838.

    Google Scholar 

  104. Blenk, H., Blenk, B., Hofstetter, A., Schmiedt, W. Activity of erythromycin againstChlamydiae in vitro and in vivo, and its use in genitalChlamydia infections. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 61–68.

    Google Scholar 

  105. Werner, H. Zur In-vitro-Aktivität von Erythromycin und Clindamycin/Lincomycin gegenüber Anaerobiern. Infection 5 Suppl. 1 (1977) 58–65.

    Google Scholar 

  106. Werner, H., Lang, N., Krasemann, C., Tolkmitt, G., Feddern, R. Epidemiology of anaerobic infections of the female genitourinary tract, and preliminary results of therapy with erythromycin. Curr. Med. Res. Opinion 5 Suppl. 2 (1978) 52–55.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum der Hygiene, Abteilung für Medizinische Mikrobiologie der Johann-Wolfgang-von-Goethe-Universität, Paul-Ehrlich-Str. 40, D-6000, Frankfurt 70

    G. A. Dette

Authors
  1. G. A. Dette
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Prof.H. Knothe zum 60. Geburtstag.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dette, G.A. Vergleich der Gewebegängigkeit von Erythromycin. Infection 7, 129–145 (1979). https://doi.org/10.1007/BF01641314

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01641314

Search

Navigation